京運通(601908.SH)已將合肥廣合99.9986%財產份額轉讓給聞泰科技
格隆匯10月20日丨京運通(601908.SH)公佈,根據聞泰科技公告,聞泰科技發行股份及支付現金購買資產並募集配套資金相關事項已經其第九屆董事會第四十三次會議、2019年第二次臨時股東大會審議通過。根據本公司與聞泰科技、建廣資產於2018年10月24日簽署的《資產收購協議》“第十一條協議生效”之規定,《資產收購協議》正式生效。
截至本公告披露日,標的資產交割工作的第二步財產份額轉讓已辦理完畢變更登記,公司已將持有的合肥廣合99.9986%的財產份額轉讓給聞泰科技,合肥廣合已取得新營業執照。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.